NCT06179511

Study of AZD9829 in CD123+ Hematological Malignancies

About the study

This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

≥18 years of age;
CD123+ hematologic malignancy based on flow cytometry or immunohistochemistry by local laboratory;

R/R AML (except APL);
R/R HR-MDS with ≥5% bone marrow blast at time of inclusion;
Had at least 1 prior line of therapy at currents histology, and have no available treatment options;
ECOG performance status of ≤ 2.

The above is a summary, other inclusion criteria details may apply.

EXCLUSION CRITERIA

Exclusion Criteria:

Active CNS leukemia;
Previous treatment with any CD123 targeting therapy;
Prior allogeneic HSCT, within 90 or cell therapy within 60 of start of therapy;
Active GVHD that requires immunosuppressive treatment within 4 weeks prior to start of AZD9829;
History of other malignancy(with certain exceptions);
Active and uncontrolled infections;
Unresolved AEs ≥2 Grade, from prior therapies.

The above is a summary, other exclusion criteria details may apply.